TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$250 Million

BridgeBio Pharma, Inc.


Placement Agent, September 2023

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BridgeBio or the “Company”) (NASDAQ: BBIO) is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials.